R&D News | pharmaphorum

News

Sarepta agree gene therapy R&D pact with Selecta

Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed.

News

UK team awarded grant for ‘second wave’ COVID-19 drug hunt

A UK research group has been given £2.2 million in funding to seek out additional drugs to treat COVID-19, in case the first wave of therapies fail to show a benefit.

News

Patient on hospital bed with saline solution tube

Gilead will test remdesivir in children with COVID-19

Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from newborns to adolescents – who have moderate-to-severe COVID-19.

News

US left with huge hydroxychloroquine stockpile after COVID-1...

The US has been left with a huge stockpile of hydroxychloroquine, after the World Health Organization abandoned research into the drug as a treatment for COVID-19.

News

Regeneron gets closer to ISA Pharma with new immuno-oncology...

Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch biotech and cueing up a third trial of their immuno-oncology combina

News

Royalty Pharma shares surge 59% after $2.2 billion IPO

Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s

Sarepta agree gene therapy R&D pact with Selecta

UK team awarded grant for ‘second wave’ COVID-19 drug hunt

Gilead will test remdesivir in children with COVID-19

US left with huge hydroxychloroquine stockpile after COVID-1...

Regeneron gets closer to ISA Pharma with new immuno-oncology...

Royalty Pharma shares surge 59% after $2.2 billion IPO

Lilly inflates US facility investment spending by $4.5bn

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks